Zetsyl (Capsules, Powder) Instructions for Use
ATC Code
J01CA01 (Ampicillin)
Active Substance
Ampicillin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Broad-spectrum penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Antibiotic, semi-synthetic penicillin
Pharmacological Action
A broad-spectrum antibiotic from the group of semi-synthetic penicillins. It exerts a bactericidal effect by inhibiting the synthesis of the bacterial cell wall.
It is active against aerobic gram-positive bacteria: Staphylococcus spp. (except for strains producing penicillinase), Streptococcus spp., Enterococcus spp., Listeria monocytogenes; aerobic gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Shigella spp., Salmonella spp., Bordetella pertussis, some strains of Haemophilus influenzae.
It is destroyed by bacterial β-lactamases.
Pharmacokinetics
After oral administration, it is well absorbed from the gastrointestinal tract. Ampicillin is distributed in most organs and tissues. It crosses the placental barrier and poorly penetrates the blood-brain barrier. In inflammation of the meninges, the permeability of the blood-brain barrier increases sharply. 30% of ampicillin is metabolized in the liver. It is excreted in the urine and bile.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to ampicillin: including infections of the ear, throat, nose, odontogenic infections, bronchopulmonary infections, acute and chronic infections of the genitourinary tract, gastrointestinal infections (including salmonellosis, cholecystitis), gynecological infections, meningitis, endocarditis, septicemia, sepsis, rheumatism, erysipelas, scarlet fever, infections of the skin and soft tissues.
ICD codes
| ICD-10 code | Indication |
| A02 | Other salmonella infections |
| A38 | Scarlet fever |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A46 | Erysipelas |
| G00 | Bacterial meningitis, not elsewhere classified |
| H66 | Suppurative and unspecified otitis media |
| H70 | Mastoiditis and related conditions |
| I33 | Acute and subacute endocarditis |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| K04 | Diseases of pulp and periapical tissues (including periodontitis) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M05 | Seropositive rheumatoid arthritis |
| M79.0 | Unspecified rheumatism |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A09.Z | Salmonella infection, unspecified |
| 1B50 | Scarlet fever |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| AA9Z | Unspecified suppurative otitis media |
| AB11 | Mastoiditis or related conditions |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DA09.Z | Diseases of pulp and periapical tissues, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA27.2 | Palindromic rheumatism |
| FB51.3 | Fibroblastic rheumatism |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Capsules, Powder
The dosage is set individually depending on the severity of the course, localization of the infection and the sensitivity of the pathogen.
For oral administration for adults, a single dose is 250-500 mg, the frequency of administration is 4 times/day. For children weighing up to 20 kg – 12.5-25 mg/kg every 6 hours.
For intramuscular, intravenous administration, a single dose for adults is 250-500 mg every 4-6 hours. For children, a single dose is 25-50 mg/kg.
The duration of treatment depends on the localization of the infection and the characteristics of the course of the disease.
The maximum daily dose for adults when taken orally is 4 g, with intravenous and intramuscular administration – 14 g.
Adverse Reactions
Allergic reactions urticaria, erythema, angioedema, rhinitis, conjunctivitis; rarely – fever, joint pain, eosinophilia; extremely rarely – anaphylactic shock.
From the digestive system nausea, vomiting.
Effects due to chemotherapeutic action oral candidiasis, vaginal candidiasis, intestinal dysbiosis, colitis caused by Clostridium difficile.
Contraindications
Infectious mononucleosis, lymphocytic leukemia, hypersensitivity to ampicillin and other penicillins, impaired liver function.
Use in Pregnancy and Lactation
Ampicillin can be used during pregnancy if indicated. Ampicillin is excreted in breast milk in low concentrations. If it is necessary to use ampicillin during lactation, the issue of stopping breastfeeding should be decided.
Use in Hepatic Impairment
Contraindicated in impaired liver function.
During treatment with ampicillin, systematic monitoring of liver function is necessary.
Use in Renal Impairment
Patients with impaired renal function require dose adjustment according to the creatinine clearance values.
During treatment with ampicillin, systematic monitoring of renal function is necessary. When used in high doses in patients with renal failure, a toxic effect on the central nervous system is possible.
Pediatric Use
Use is possible according to the dosage regimen.
Special Precautions
During treatment with ampicillin, systematic monitoring of kidney and liver function and the peripheral blood picture is necessary. Patients with impaired renal function require dose adjustment according to the creatinine clearance values.
When used in high doses in patients with renal failure, a toxic effect on the central nervous system is possible.
When using ampicillin in patients with bacteremia (sepsis), a bacteriolysis reaction (Jarisch-Herxheimer reaction) is possible.
Drug Interactions
Sulbactam, an irreversible β-lactamase inhibitor, prevents the hydrolysis and destruction of ampicillin by microbial β-lactamases.
With the simultaneous use of ampicillin with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin), synergism is manifested; with bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulfonamides) – antagonism.
Ampicillin enhances the effect of indirect anticoagulants by suppressing the intestinal microflora, reduces the synthesis of vitamin K and the prothrombin index.
Ampicillin reduces the effect of drugs in the metabolism of which PABA is formed.
Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs reduce the tubular secretion of ampicillin, which may be accompanied by an increase in its plasma concentration.
Antacids, glucosamine, laxatives, aminoglycosides slow down and reduce the absorption of ampicillin. Ascorbic acid increases the absorption of ampicillin.
Ampicillin reduces the effectiveness of oral contraceptives.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Capsules 250 mg: 20 pcs.
Marketing Authorization Holder
Aurobindo Pharma, Ltd. (India)
Dosage Form
| Zetsyl | Capsules 250 mg: 20 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Ampicillin (as trihydrate) | 250 mg |
10 pcs. – blister packs (2) – cardboard packs.
Capsules 500 mg: 20 pcs.
Marketing Authorization Holder
Aurobindo Pharma, Ltd. (India)
Dosage Form
| Zetsyl | Capsules 500 mg: 20 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Ampicillin (as trihydrate) | 500 mg |
10 pcs. – blister packs (2) – cardboard packs.
Powder for solution for injection 500 mg: fl. 10 pcs.
Marketing Authorization Holder
Aurobindo Pharma, Ltd. (India)
Dosage Form
| Zetsyl | Powder for solution for injection 500 mg: fl. 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for injection | 1 fl. |
| Ampicillin (as sodium salt) | 500 mg |
Vials (1) – cardboard packs.
Powder for solution for injection 1 g: fl. 10 pcs.
Marketing Authorization Holder
Aurobindo Pharma, Ltd. (India)
Dosage Form
| Zetsyl | Powder for solution for injection 1 g: fl. 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for injection | 1 fl. |
| Ampicillin (as sodium salt) | 1 g |
1 g – vials (1) – cardboard packs.
Actovegin pills 200mg, 50pcs
Ingavirin capsules 90mg, 10pcs
Daivobet, ointment, 30g
Noopept, pills 10mg, 50pcs
OKI, sachets 80mg 2g, 12pcs
Fenotropil pills 100mg, 60pcs
Picamilon pills 50mg, 60pcs
Cortexin, 10mg, 5ml, 10pcs
Kagocel pills 12mg, 30pcs
Phenibut-Vertex pills 250mg, 20pcs 